TY - JOUR
T1 - Association of FADS1/2 Locus Variants and Polyunsaturated Fatty Acids with Aortic Stenosis
AU - Chen, Hao Yu
AU - Cairns, Benjamin J.
AU - Small, Aeron M.
AU - Burr, Hannah A.
AU - Ambikkumar, Athithan
AU - Martinsson, Andreas
AU - Thériault, Sébastien
AU - Munter, Hans Markus
AU - Steffen, Brian
AU - Zhang, Richard
AU - Levinson, Rebecca T.
AU - Shaffer, Christian M.
AU - Rong, Jian
AU - Sonestedt, Emily
AU - Dufresne, Line
AU - Ljungberg, Johan
AU - Näslund, Ulf
AU - Johansson, Bengt
AU - Ranatunga, Dilrini K.
AU - Whitmer, Rachel A.
AU - Budoff, Matthew J.
AU - Nguyen, Albert
AU - Vasan, Ramachandran S.
AU - Larson, Martin G.
AU - Harris, William S.
AU - Damrauer, Scott M.
AU - Stark, Ken D.
AU - Boekholdt, S. Matthijs
AU - Wareham, Nicholas J.
AU - Pibarot, Philippe
AU - Arsenault, Benoit J.
AU - Mathieu, Patrick
AU - Gudnason, Vilmundur
AU - O'Donnell, Christopher J.
AU - Rotter, Jerome I.
AU - Tsai, Michael Y.
AU - Post, Wendy S.
AU - Clarke, Robert
AU - Söderberg, Stefan
AU - Bossé, Yohan
AU - Wells, Quinn S.
AU - Smith, J. Gustav
AU - Rader, Daniel J.
AU - Lathrop, Mark
AU - Engert, James C.
AU - Thanassoulis, George
N1 - Publisher Copyright:
© 2020 American Medical Association. All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - Importance: Aortic stenosis (AS) has no approved medical treatment. Identifying etiological pathways for AS could identify pharmacological targets. Objective: To identify novel genetic loci and pathways associated with AS. Design, Setting, and Participants: This genome-wide association study used a case-control design to evaluate 44703 participants (3469 cases of AS) of self-reported European ancestry from the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort (from January 1, 1996, to December 31, 2015). Replication was performed in 7 other cohorts totaling 256926 participants (5926 cases of AS), with additional analyses performed in 6942 participants from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. Follow-up biomarker analyses with aortic valve calcium (AVC) were also performed. Data were analyzed from May 1, 2017, to December 5, 2019. Exposures: Genetic variants (615643 variants) and polyunsaturated fatty acids (ω-6 and ω-3) measured in blood samples. Main Outcomes and Measures: Aortic stenosis and aortic valve replacement defined by electronic health records, surgical records, or echocardiography and the presence of AVC measured by computed tomography. Results: The mean (SD) age of the 44703 GERA participants was 69.7 (8.4) years, and 22019 (49.3%) were men. The rs174547 variant at the FADS1/2 locus was associated with AS (odds ratio [OR] per C allele, 0.88; 95% CI, 0.83-0.93; P = 3.0 × 10-6), with genome-wide significance after meta-analysis with 7 replication cohorts totaling 312118 individuals (9395 cases of AS) (OR, 0.91; 95% CI, 0.88-0.94; P = 2.5 × 10-8). A consistent association with AVC was also observed (OR, 0.91; 95% CI, 0.83-0.99; P =.03). A higher ratio of arachidonic acid to linoleic acid was associated with AVC (OR per SD of the natural logarithm, 1.19; 95% CI, 1.09-1.30; P = 6.6 × 10-5). In mendelian randomization, increased FADS1 liver expression and arachidonic acid were associated with AS (OR per unit of normalized expression, 1.31 [95% CI, 1.17-1.48; P = 7.4 × 10-6]; OR per 5-percentage point increase in arachidonic acid for AVC, 1.23 [95% CI, 1.01-1.49; P =.04]; OR per 5-percentage point increase in arachidonic acid for AS, 1.08 [95% CI, 1.04-1.13; P = 4.1 × 10-4]). Conclusions and Relevance: Variation at the FADS1/2 locus was associated with AS and AVC. Findings from biomarker measurements and mendelian randomization appear to link ω-6 fatty acid biosynthesis to AS, which may represent a therapeutic target.
AB - Importance: Aortic stenosis (AS) has no approved medical treatment. Identifying etiological pathways for AS could identify pharmacological targets. Objective: To identify novel genetic loci and pathways associated with AS. Design, Setting, and Participants: This genome-wide association study used a case-control design to evaluate 44703 participants (3469 cases of AS) of self-reported European ancestry from the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort (from January 1, 1996, to December 31, 2015). Replication was performed in 7 other cohorts totaling 256926 participants (5926 cases of AS), with additional analyses performed in 6942 participants from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. Follow-up biomarker analyses with aortic valve calcium (AVC) were also performed. Data were analyzed from May 1, 2017, to December 5, 2019. Exposures: Genetic variants (615643 variants) and polyunsaturated fatty acids (ω-6 and ω-3) measured in blood samples. Main Outcomes and Measures: Aortic stenosis and aortic valve replacement defined by electronic health records, surgical records, or echocardiography and the presence of AVC measured by computed tomography. Results: The mean (SD) age of the 44703 GERA participants was 69.7 (8.4) years, and 22019 (49.3%) were men. The rs174547 variant at the FADS1/2 locus was associated with AS (odds ratio [OR] per C allele, 0.88; 95% CI, 0.83-0.93; P = 3.0 × 10-6), with genome-wide significance after meta-analysis with 7 replication cohorts totaling 312118 individuals (9395 cases of AS) (OR, 0.91; 95% CI, 0.88-0.94; P = 2.5 × 10-8). A consistent association with AVC was also observed (OR, 0.91; 95% CI, 0.83-0.99; P =.03). A higher ratio of arachidonic acid to linoleic acid was associated with AVC (OR per SD of the natural logarithm, 1.19; 95% CI, 1.09-1.30; P = 6.6 × 10-5). In mendelian randomization, increased FADS1 liver expression and arachidonic acid were associated with AS (OR per unit of normalized expression, 1.31 [95% CI, 1.17-1.48; P = 7.4 × 10-6]; OR per 5-percentage point increase in arachidonic acid for AVC, 1.23 [95% CI, 1.01-1.49; P =.04]; OR per 5-percentage point increase in arachidonic acid for AS, 1.08 [95% CI, 1.04-1.13; P = 4.1 × 10-4]). Conclusions and Relevance: Variation at the FADS1/2 locus was associated with AS and AVC. Findings from biomarker measurements and mendelian randomization appear to link ω-6 fatty acid biosynthesis to AS, which may represent a therapeutic target.
UR - http://www.scopus.com/inward/record.url?scp=85082412919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082412919&partnerID=8YFLogxK
U2 - 10.1001/jamacardio.2020.0246
DO - 10.1001/jamacardio.2020.0246
M3 - Article
C2 - 32186652
AN - SCOPUS:85082412919
SN - 2380-6583
VL - 5
SP - 694
EP - 702
JO - JAMA Cardiology
JF - JAMA Cardiology
IS - 6
ER -